Logo Image
|Articles|July 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-07-01-2001
  • Volume 0
  • Issue 0

Submerged

Is the pharmaceutical industry surrounded by its critics? Can the industry be liberated from the moral bind others want to impose on it? Those are questions I asked and attempted to answer in two recent editorials (PE April and June 2001). Actually, the simple answer was yes to both. But other answers prove more complex.

Articles in this issue

about 25 years ago

Pharmacies: OTC Price Wars

about 25 years ago

One Disease at a Time

about 25 years ago

Overview of the Industry: A World of Opportunities

about 25 years ago

The Power Shift

about 25 years ago

A Giant Stumbles

about 25 years ago

Overruled: No More Dual Pricing

about 25 years ago

Generic Threat

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more